Transfusion reactions: prevention, diagnosis, and treatment

The Lancet

Volumn 388, Issue 10061, 2016, Pages 2825-2836

  Delaney, Meghan ^a,b   Wendel, Silvano ^c   Bercovitz, Rachel S ^d   Cid, Joan ^e   Cohn, Claudia ^f   Dunbar, Nancy M ^g   Apelseth, Torunn O ^h   Popovsky, Mark ⁱ   Stanworth, Simon J ^j,k   Tinmouth, Alan ^l,m   Van De Watering, Leo ⁿ   Waters, Jonathan H ^o   Yazer, Mark ^p   Ziman, Alyssa ^q  

^a Bloodworks NW ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HOSPITAL SÍRIO LIBANÊS   (Brazil)

^d BLOOD RESEARCH INSTITUTE   (United States)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^h HAUKELAND UNIVERSITY HOSPITAL   (Norway)

ⁱ HAEMONETICS CORPORATION   (United States)

^j JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l UNIVERSITY OF OTTAWA   (Canada)

^m OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

ⁿ Center for Clinical Transfusion Reseach Sanquin LUMC   (Netherlands)

^o UNIVERSITY OF PITTSBURGH   (United States)

^p UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIHISTAMINIC AGENT; BETA LACTAM; BRONCHODILATING AGENT; CITRIC ACID; CORTICOSTEROID; GLUCOCORTICOID; POTASSIUM;

ALLERGIC REACTION; ANAPHYLAXIS; BLOOD TRANSFUSION REACTION; DELAYED SEROLOGICAL TRANSFUSION REACTION; EVIDENCE BASED PRACTICE; FEBRILE NON HAEMOLYTIC REACTION; HUMAN; HYPERHAEMOLYTIC TRANSFUSION REACTION; HYPOTENSION; HYPOTENSIVE TRANSFUSION REACTION; MASSIVE TRANSFUSION ASSOCIATED REACTION; POST TRANSFUSION PURPURA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPTIC TRANSFUSION REACTION; TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; TRANSFUSION ASSOCIATED NECROTISING ENTEROCOLITIS; TRANSFUSION RELATED ACUTE LUNG INJURY; ADVERSE EFFECTS; BLOOD TRANSFUSION; EVIDENCE BASED MEDICINE; PATHOPHYSIOLOGY; PROCEDURES; STANDARDS; TRANSFUSION REACTION;

BLOOD TRANSFUSION; EVIDENCE-BASED MEDICINE; HUMANS; TRANSFUSION REACTION;

EID: 84964330197     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01313-6     Document Type: Review

References (119)

1. 1 Pfuntner, A, Wier, LM, Stocks, C, Most Frequent Procedures Performed in U.S. Hospitals, 2011, 2013, Agency for Healthcare Research and Quality, Rockville.
2. 2 Callum, JL, Waters, JH, Shaz, BH, Sloan, SR, Murphy, MF, The AABB recommendations for the Choosing Wisely campaign of the American Board of Internal Medicine. Transfusion 54 (2014), 2344–2352.
3. 3 Bolton-Maggs, PHB, on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group, (eds.) The 2013 Annual SHOT Report, 2014, SHOT, Manchester.
4. 4 Riley, W, Smalley, B, Pulkrabek, S, Clay, ME, McCullough, J, Using lean techniques to define the platelet (PLT) transfusion process and cost-effectiveness to evaluate PLT dose transfusion strategies. Transfusion 52 (2012), 1957–1967.
5. 5 Ezidiegwu, CN, Lauenstein, KJ, Rosales, LG, Kelly, KC, Henry, JB, Febrile nonhemolytic transfusion reactions. Management by premedication and cost implications in adult patients. Arch Pathol Lab Med 128 (2004), 991–995.
6. 6 Bolton-Maggs, PH, Bullet points from SHOT: key messages and recommendations from the Annual SHOT Report 2013. Transfus Med 24 (2014), 197–203.
7. 7 CDC. NHSN Biovigilance Component, Hemovigilance Module Surveillance Protocol v2.1.3, 2014, Centers for Disease Control and Prevention, Atlanta.
8. 8 Guyatt, G, Gutterman, D, Baumann, MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 129 (2006), 174–181.
9. 9 Elliott, M, Coventry, A, Critical care: the eight vital signs of patient monitoring. Br J Nurs 21 (2012), 621–625.
10. 10 Fung, M, Grossman, BJ, Hillyer, CD, Westhoff, CM, Technical Manual, 18th edn., 2014, AABB Press, Glen Burnie, MD.
11. 11 Harvey, AR, Basavaraju, SV, Chung, KW, Kuehnert, MJ, Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012. Transfusion, 2014, 10.1111/trf.12918 published online Nov 5.
12. 12 Hirayama, F, Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br J Haematol 160 (2013), 434–444.
13. 13 Simons, FE, Ardusso, LR, Bilò, MB, et al., the World Allergy Organization. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol, 127, 2011, 587 e1–22.
14. 14 Tinegate, H, Birchall, J, Gray, A, et al., the BCSH Blood Transfusion Task Force. Guideline on the investigation and management of acute transfusion reactions. Prepared by the BCSH Blood Transfusion Task Force. Br J Haematol 159 (2012), 143–153.
15. 15 Lin, RY, Curry, A, Pesola, GR, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med 36 (2000), 462–468.
16. 16 Runge, JW, Martinez, JC, Caravati, EM, Williamson, SG, Hartsell, SC, Histamine antagonists in the treatment of acute allergic reactions. Ann Emerg Med 21 (1992), 237–242.
17. 17 Martí-Carvajal, AJ, Solà, I, González, LE, Leon de Gonzalez, G, Rodriguez-Malagon, N, Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions. Cochrane Database Syst Rev, 6, 2010 CD007539.
18. 18 Cohn, CS, Stubbs, J, Schwartz, J, et al. A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion 54 (2014), 1927–1934.
19. 19 Tobian, AA, Savage, WJ, Tisch, DJ, Thoman, S, King, KE, Ness, PM, Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction. Transfusion 51 (2011), 1676–1683.
20. 20 Sandler, SG, Eder, AF, Goldman, M, Winters, JL, The entity of immunoglobulin A-related anaphylactic transfusion reactions is not evidence based. Transfusion 55 (2015), 199–204.
21. 21 Weinstock, C, Möhle, R, Dorn, C, et al. Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion. Transfusion 55 (2015), 605–610.
22. 22 Fredlund, H, Berséus, O, Björsell-Ostlilng, E, Filbey, D, A retrospective study of acute plasma exchange in severe intravascular hemolysis. Eur J Haematol 43 (1989), 259–261.
23. 23 Seager, OA, Nesmith, MA, Begelman, KA, et al. Massive acute hemodilution for incompatible blood reaction. JAMA 229 (1974), 790–792.
24. 24 Kohan, AI, Niborski, RC, Rey, JA, et al. High-dose intravenous immunoglobulin in non-ABO transfusion incompatibility. Vox Sang 67 (1994), 195–198.
25. 25 Figueroa, PI, Ziman, A, Wheeler, C, Gornbein, J, Monson, M, Calhoun, L, Nearly two decades using the check-type to prevent ABO incompatible transfusions: one institution's experience. Am J Clin Pathol 126 (2006), 422–426.
26. 26 Goodnough, LT, Viele, M, Fontaine, MJ, et al. Implementation of a two-specimen requirement for verification of ABO/Rh for blood transfusion. Transfusion 49 (2009), 1321–1328.
27. 27 Strautz, RL, Nelson, JM, Meyer, EA, Shulman, IA, Compatibility of ADSOL-stored red cells with intravenous solutions. Am J Emerg Med 7 (1989), 162–164.
28. 28 McCullough, J, Polesky, HF, Nelson, C, Hoff, T, Iatrogenic hemolysis: a complication of blood warmed by a microwave device. Anesth Analg 51 (1972), 102–106.
29. 29 Talano, JA, Hillery, CA, Gottschall, JL, Baylerian, DM, Scott, JP, Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 111 (2003), e661–e665.
30. 30 Schonewille, H, Haak, HL, van Zijl, AM, RBC antibody persistence. Transfusion 40 (2000), 1127–1131.
31. 31 Unni, N, Peddinghaus, M, Tormey, CA, Stack, G, Record fragmentation due to transfusion at multiple health care facilities: a risk factor for delayed hemolytic transfusion reactions. Transfusion 54 (2014), 98–103.
32. 32 Rosse, WF, Gallagher, D, Kinney, TR, et al., the The Cooperative Study of Sickle Cell Disease. Transfusion and alloimmunization in sickle cell disease. Blood 76 (1990), 1431–1437.
33. 33 de Montalembert, M, Dumont, MD, Heilbronner, C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica 96 (2011), 801–807.
34. 34 Ness, PM, Shirey, RS, Thoman, SK, Buck, SA, The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. Transfusion 30 (1990), 688–693.
35. 35 Vamvakas, EC, Pineda, AA, Reisner, R, Santrach, PJ, Moore, SB, The differentiation of delayed hemolytic and delayed serologic transfusion reactions: incidence and predictors of hemolysis. Transfusion 35 (1995), 26–32.
36. 36 Noizat-Pirenne, F, Relevance of blood groups in transfusion of sickle cell disease patients. C R Biol 336 (2013), 152–158.
37. 37 Koshy, R, Patel, B, Harrison, JS, Anti-Kpa-induced severe delayed hemolytic transfusion reaction. Immunohematology 25 (2009), 44–47.
38. 38 Tormey, CA, Stack, G, Limiting the extent of a delayed hemolytic transfusion reaction with automated red blood cell exchange. Arch Pathol Lab Med 137 (2013), 861–864.
39. 39 Noizat-Pirenne, F, Habibi, A, Mekontso-Dessap, A, et al. The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease. Vox Sang 108 (2015), 262–267.
40. 40 Winters, JL, Richa, EM, Bryant, SC, Tauscher, CD, Bendix, BJ, Stubbs, JR, Polyethylene glycol antiglobulin tube versus gel microcolumn: influence on the incidence of delayed hemolytic transfusion reactions and delayed serologic transfusion reactions. Transfusion 50 (2010), 1444–1452.
41. 41 Harm, SK, Yazer, MH, Monis, GF, Triulzi, DJ, Aubuchon, JP, Delaney, M, A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease. Am J Clin Pathol 141 (2014), 256–261.
42. 42 Delaney, M, Dinwiddie, S, Nester, TN, Aubuchon, JA, The immunohematologic and patient safety benefits of a centralized transfusion database. Transfusion 53 (2013), 771–776.
43. 43 Schwickerath, V, Kowalski, M, Menitove, JE, Regional registry of patient alloantibodies: first-year experience. Transfusion 50 (2010), 1465–1470.
44. 44 Vichinsky, EP, Luban, NL, Wright, E, et al., the Stroke Prevention Trail in Sickle Cell Anemia. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 41 (2001), 1086–1092.
45. 45 Lasalle-Williams, M, Nuss, R, Le, T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion 51 (2011), 1732–1739.
46. 46 Chou, ST, Jackson, T, Vege, S, Smith-Whitley, K, Friedman, DF, Westhoff, CM, High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 122 (2013), 1062–1071.
47. 47 Pujani, M, Pahuja, S, Dhingra, B, Chandra, J, Jain, M, Alloimmunisation in thalassaemics: a comparison between recipients of usual matched and partial better matched blood. An evaluation at a tertiary care centre in India. Blood Transfus 12:suppl 1 (2014), s100–s104.
48. 48 Sanders, RP, Maddirala, SD, Geiger, TL, et al. Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children. Br J Haematol 130 (2005), 781–787.
49. 49 Heddle, NM, Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol 6 (1999), 420–426.
50. 50 Jacobs, MR, Smith, D, Heaton, WA, Zantek, ND, Good, CE, the PGD Study Group. Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. Transfusion 51 (2011), 2573–2582.
51. 51 Friedlander, M, Noble, WH, Meperidine to control shivering associated with platelet transfusion reaction. Can J Anaesth 36 (1989), 460–462.
52. 52 Heddle, NM, Blajchman, MA, Meyer, RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 42 (2002), 556–566 http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/825/CN-00389825/frame.html (serial online).
53. 53 Kennedy, LD, Case, LD, Hurd, DD, Cruz, JM, Pomper, GJ, A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. Transfusion 48 (2008), 2285–2291.
54. 54 Diamond, WJ, Brown, FL Jr, Bitterman, P, Klein, HG, Davey, RJ, Winslow, RM, Delayed hemolytic transfusion reaction presenting as sickle-cell crisis. Ann Intern Med 93 (1980), 231–234.
55. 55 Garratty, G, What do we mean by “Hyperhaemolysis” and what is the cause?. Transfus Med 22 (2012), 77–79.
56. 56 Darabi, K, Dzik, S, Hyperhemolysis syndrome in anemia of chronic disease. Transfusion 45 (2005), 1930–1933.
57. 57 Win, N, New, H, Lee, E, de la Fuente, J, Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion 48 (2008), 1231–1238.
58. 58 Win, N, Sinha, S, Lee, E, Mills, W, Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review. Transfus Med Rev 24 (2010), 64–67.
59. 59 Uhlmann, EJ, Shenoy, S, Goodnough, LT, Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion. Transfusion 54 (2014), 384–388.
60. 60 Gupta, S, Fenves, A, Nance, ST, Sykes, DB, Dzik, WS, Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab. Transfusion 55 (2015), 623–628.
61. 61 Whitaker, BI, National Blood Collection and Utilization Survey 2011. Report number HHSP23320110008TC, OMB Number 0990-0313, 2011, AABB, Bethesda.
62. 62 Moreau, ME, Thibault, L, Désormeaux, A, et al. Generation of kinins during preparation and storage of whole blood-derived platelet concentrates. Transfusion 47 (2007), 410–420.
63. 63 Sweeney, JD, Dupuis, M, Mega, AP, Hypotensive reactions to red cells filtered at the bedside, but not to those filtered before storage, in patients taking ACE inhibitors. Transfusion 38 (1998), 410–411 author reply 413–15.
64. 64 Takahashi, TA, Abe, H, Hosoda, M, Nakai, K, Sekiguchi, S, Bradykinin generation during filtration of platelet concentrates with a white cell-reduction filter. Transfusion, 35, 1995, 967.
65. 65 Pagano, MB, Ness, PM, Chajewski, OS, King, KE, Wu, Y, Tobian, AA, Hypotensive transfusion reactions in the era of prestorage leukoreduction. Transfusion 55 (2015), 1668–1674.
66. 66 Arnold, DM, Molinaro, G, Warkentin, TE, et al. Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage. Transfusion 44 (2004), 1361–1366.
67. 67 Cyr, M, Eastlund, T, Blais, C Jr, Rouleau, JL, Adam, A, Bradykinin metabolism and hypotensive transfusion reactions. Transfusion 41 (2001), 136–150.
68. 68 Owen, HG, Brecher, ME, Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion 34 (1994), 891–894.
69. 69 Kalra, A, Palaniswamy, C, Patel, R, Kalra, A, Selvaraj, DR, Acute hypotensive transfusion reaction with concomitant use of angiotensin-converting enzyme inhibitors: a case report and review of the literature. Am J Ther 19 (2012), e90–e94.
70. 70 Doria, C, Elia, ES, Kang, Y, et al. Acute hypotensive transfusion reaction during liver transplantation in a patient on angiotensin converting enzyme inhibitors from low aminopeptidase P activity. Liver Transpl 14 (2008), 684–687.
71. 71 Sihler, KC, Napolitano, LM, Complications of massive transfusion. Chest 137 (2010), 209–220.
72. 72 Dzik, WH, Kirkley, SA, Citrate toxicity during massive blood transfusion. Transfus Med Rev 2 (1988), 76–94.
73. 73 Olinger, GN, Hottenrott, C, Mulder, DG, et al. Acute clinical hypocalcemic myocardial depression during rapid blood transfusion and postoperative hemodialysis: a preventable complication. J Thorac Cardiovasc Surg 72 (1976), 503–511.
74. 74 Meikle, A, Milne, B, Management of prolonged QT interval during a massive transfusion: calcium, magnesium or both?. Can J Anaesth 47 (2000), 792–795.
75. 75 Strauss, RG, RBC storage and avoiding hyperkalemia from transfusions to neonates & infants. Transfusion 50 (2010), 1862–1865.
76. 76 Lee, AC, Reduque, LL, Luban, NL, Ness, PM, Anton, B, Heitmiller, ES, Transfusion-associated hyperkalemic cardiac arrest in pediatric patients receiving massive transfusion. Transfusion 54 (2014), 244–254.
77. 77 Sesok-Pizzini, D, Pizzini, MA, Hyperkalemic cardiac arrest in pediatric patients undergoing massive transfusion: unplanned emergencies. Transfusion 54 (2014), 4–7.
78. 78 Weiskopf, RB, Schnapp, S, Rouine-Rapp, K, Bostrom, A, Toy, P, Extracellular potassium concentrations in red blood cell suspensions after irradiation and washing. Transfusion 45 (2005), 1295–1301.
79. 79 Inaba, S, Nibu, K, Takano, H, et al. Potassium-adsorption filter for RBC transfusion: a phase III clinical trial. Transfusion 40 (2000), 1469–1474.
80. 80 Delaney, M, Axdorff-Dickey, RL, Crockett, GI, Falconer, AL, Levario, MJ, McMullan, DM, Risk of extracorporeal life support circuit-related hyperkalemia is reduced by prebypass ultrafiltration. Pediatr Crit Care Med 14 (2013), e263–e267.
81. 81 Boyan, CP, Cold or warmed blood for massive transfusions. Ann Surg 160 (1964), 282–286.
82. 82 Moola, S, Lockwood, C, Effectiveness of strategies for the management and/or prevention of hypothermia within the adult perioperative environment. Int J Evid-Based Healthc 9 (2011), 337–345.
83. 83 Leslie, K, Sessler, DI, Perioperative hypothermia in the high-risk surgical patient. Best Pract Res Clin Anaesthesiol 17 (2003), 485–498.
84. 84 Gonzalez, CE, Pengetze, YM, Post-transfusion purpura. Curr Hematol Rep 4 (2005), 154–159.
85. 85 Kalish, RI, Jacobs, B, Post-transfusion purpura: initiation by leukocyte-poor red cells in a polytransfused woman. Vox Sang 53 (1987), 169–172.
86. 86 Menis, M, Forshee, RA, Anderson, SA, et al. Posttransfusion purpura occurrence and potential risk factors among the inpatient US elderly, as recorded in large Medicare databases during 2011 through 2012. Transfusion 55 (2015), 284–295.
87. 87 Mueller-Eckhardt, C, Kiefel, V, High-dose IgG for post-transfusion purpura-revisited. Blut 57 (1988), 163–167.
88. 88 Win, N, Peterkin, MA, Watson, WH, The therapeutic value of HPA-1a-negative platelet transfusion in post-transfusion purpura complicated by life-threatening haemorrhage. Vox Sang 69 (1995), 138–139.
89. 89 Williamson, LM, Stainsby, D, Jones, H, et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion 47 (2007), 1455–1467.
90. 90 Funk, MB, Lohmann, A, Guenay, S, et al. Transfusion-transmitted bacterial infections – haemovigilance data of German blood establishments (1997-2010). Transfus Med Hemother 38 (2011), 266–271.
91. 91 Robillard, P, Delage, G, Itaj, NK, Goldman, M, Use of hemovigilance data to evaluate the effectiveness of diversion and bacterial detection. Transfusion 51 (2011), 1405–1411.
92. 92 Lafeuillade, B, Eb, F, Ounnoughene, N, et al. Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance Network from 2000 to 2008. Transfusion 55 (2015), 636–646.
93. 93 Eder, AF, Goldman, M, How do I investigate septic transfusion reactions and blood donors with culture-positive platelet donations?. Transfusion 51 (2011), 1662–1668.
94. 94 Katus, MC, Szczepiorkowski, ZM, Dumont, LJ, Dunbar, NM, Safety of platelet transfusion: past, present and future. Vox Sang 107 (2014), 103–113.
95. 95 Murphy, WG, Coakley, P, Testing platelet components for bacterial contamination. Transfus Apher Sci 45 (2011), 69–74.
96. 96 Lin, L, Dikeman, R, Molini, B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 44 (2004), 1496–1504.
97. 97 Zavizion, B, Serebryanik, D, Chapman, J, Alford, B, Purmal, A, Inactivation of Gram-negative and Gram-positive bacteria in red cell concentrates using INACTINE PEN110 chemistry. Vox Sang 87 (2004), 143–149.
98. 98 Amsler, L, Jutzi, M, Haemovigilance annual report 2014, 2015, Swissmedic, Berne.
99. 99 Narick, C, Triulzi, DJ, Yazer, MH, Transfusion-associated circulatory overload after plasma transfusion. Transfusion 52 (2012), 160–165.
100. 100 Andrzejewski, C Jr, Casey, MA, Popovsky, MA, How we view and approach transfusion-associated circulatory overload: pathogenesis, diagnosis, management, mitigation, and prevention. Transfusion 53 (2013), 3037–3047.
101. 101 Lieberman, L, Maskens, C, Cserti-Gazdewich, C, et al. A retrospective review of patient factors, transfusion practices, and outcomes in patients with transfusion-associated circulatory overload. Transfus Med Rev 27 (2013), 206–212.
102. 102 Piccin, A, Cronin, M, Brady, R, Sweeney, J, Marcheselli, L, Lawlor, E, Transfusion-associated circulatory overload in Ireland: a review of cases reported to the National Haemovigilance Office 2000 to 2010. Transfusion 55 (2015), 1223–1230.
103. 103 Andrzejewski, C Jr, Popovsky, MA, Stec, TC, et al. Hemotherapy bedside biovigilance involving vital sign values and characteristics of patients with suspected transfusion reactions associated with fluid challenges: can some cases of transfusion-associated circulatory overload have proinflammatory aspects?. Transfusion 52 (2012), 2310–2320.
104. 104 Anderson, KC, Weinstein, HJ, Transfusion-associated graft-versus-host disease. N Engl J Med 323 (1990), 315–321.
105. 105 Rühl, H, Bein, G, Sachs, UJ, Transfusion-associated graft-versus-host disease. Transfus Med Rev 23 (2009), 62–71.
106. 106 Ohto, H, Yasuda, H, Noguchi, M, Abe, R, Risk of transfusion-associated graft-versus-host disease as a result of directed donations from relatives. Transfusion 32 (1992), 691–693.
107. 107 Treleaven, J, Gennery, A, Marsh, J, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol 152 (2011), 35–51.
108. 108 Marschner, S, Fast, LD, Baldwin, WM 3rd, Slichter, SJ, Goodrich, RP, White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 50 (2010), 2489–2498.
109. 109 Kirpalani, H, Zupancic, JA, Do transfusions cause necrotizing enterocolitis? The complementary role of randomized trials and observational studies. Semin Perinatol 36 (2012), 269–276.
110. 110 Mohamed, A, Shah, PS, Transfusion associated necrotizing enterocolitis: a meta-analysis of observational data. Pediatrics 129 (2012), 529–540.
111. 111 Kenton, AB, Hegemier, S, Smith, EO, et al. Platelet transfusions in infants with necrotizing enterocolitis do not lower mortality but may increase morbidity. J Perinatol 25 (2005), 173–177.
112. 112 El-Dib, M, Narang, S, Lee, E, Massaro, AN, Aly, H, Red blood cell transfusion, feeding and necrotizing enterocolitis in preterm infants. J Perinatol 31 (2011), 183–187.
113. 113 Toy, P, Gajic, O, Bacchetti, P, et al., the TRALI Study Group. Transfusion-related acute lung injury: incidence and risk factors. Blood 119 (2012), 1757–1767.
114. 114 Sayah, DM, Looney, MR, Toy, P, Transfusion reactions: newer concepts on the pathophysiology, incidence, treatment, and prevention of transfusion-related acute lung injury. Crit Care Clin 28 (2012), 363–372 v.
115. 115 Shaz, BH, Bye-bye TRALI: by understanding and innovation. Blood 123 (2014), 3374–3376.
116. 116 Silliman, CC, Kelher, MR, Khan, SY, et al. Experimental prestorage filtration removes antibodies and decreases lipids in RBC supernatants mitigating TRALI in vivo. Blood 123 (2014), 3488–3495.
117. 117 Vlaar, AP, Juffermans, NP, Transfusion-related acute lung injury: a clinical review. Lancet 382 (2013), 984–994.
118. 118 Van der Linden, P, Lambermont, M, Dierick, A, et al., for the Working Group of the Superior Health Council. Recommendations in the event of a suspected transfusion-related acute lung injury (TRALI). Acta Clin Belg 67 (2012), 201–208.
119. 119 Toy, P, Popovsky, MA, Abraham, E, et al. for the National Heart, Lung and Blood Institute Working Group on TRALI. Transfusion-related acute lung injury: definition and review. Crit Care Med 33 (2005), 721–726.